WEBINAR SERIES

  1. Home
  2. Webinars
  3. February 2023

ISLH Webinar:"How to Interpret NGS Reports in the Diagnosis of Hematological Neoplasms"

Speakers

Patrizia Chiusolo, Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma-Italy


""Diagnostic Flow Cytometry: Case-Based Problem Solving" as presented at the 2022 WASPaLM Meeting, Punta del Este, Uruguay, October 1, 2022"

Learning Objectives:

  • Define the basis of NGS.

  • Explain the difference between whole-genome sequencing, whole exome sequencing and hot spot panels and identify the best option for clinical application.

  • How to interpret mutations.


    • Click Here for Q&A



    Watch the Webinar





    Answers to Questions from Live Webinar

    Below is a list of questions received from the live webinar attendees. Click on any question to reveal the speaker's response.

    NEW QUESTION/ANSWER

    It is common to see necrosis in cHL, hard to put a number on it offhand.

    NEW QUESTION/ANSWER

    Classic in the 2017 WHO

    NEW QUESTION/ANSWER

    It can be expressed in both CHL and ALCL so it may not be reliable.

    NEW QUESTION/ANSWER

    CD15, CD30, CD20, PAX5, OCT2, BOB1 and CD45 can be helpful.

    NEW QUESTION/ANSWER

    I have never seen this.

    NEW QUESTION/ANSWER

    No, there is no clinical role for this at present.

    NEW QUESTION/ANSWER

    This would be highly unusual

    NEW QUESTION/ANSWER

    I don’t have any experience with J chain but is usually negative in RS-cells. MUM1 is typically positive but not specific.

    NEW QUESTION/ANSWER

    No

    NEW QUESTION/ANSWER

    Yes. J-chain and MEF2B have been reported to be useful as well. PMID: 28851661

    NEW QUESTION/ANSWER

    I don’t think it is particularly helpful, some cases of cHL may have rearranged IGH

    NEW QUESTION/ANSWER

    No

    NEW QUESTION/ANSWER

    I don’t find it that helpful

    NEW QUESTION/ANSWER

    There has been some data to suggest it is prognostic.

    NEW QUESTION/ANSWER

    It does not appear to commonly result in loss of CD30 expression in follow-up biopsy but I don’t believe this has been extensively studied.

    NEW QUESTION/ANSWER

    Yes, for T-cell lymphomas including cutaneous T-cell lymphomas it is reasonable to report the % positive tumor cells because some trials that resulted in the approval of brentuximab used specific cutoffs.